Lilly aquisition of Pfizer Animal Health
A deal has been agreed between Pfizer Animal Health and Lilly which sees a transfer of a number of Pfizer’s assets to Lilly.
The agreement includes the acquisition of one of their Sligo Manufacturing Plants. All staff will be offered positions with Lilly.
European rights to many vaccines, parasiticides and feed additives are being sold off to Elanco, Lilly’s animal health division as part and parcel of its recent procurement of competitor Wyeth.
With the closing of this deal still to be approved, Pfizer are said to be receiving an undisclosed payment upfront.
President of Elanco, Jeff Simmons has welcomed the procurement, saying that Pfizer’s portfolio and plant is “a natural fit for Elanco and positions us well for sustained growth”
“Through this acquisition, we will expand and diversify our European presence with new market-leading products, augment our growing portfolio of companion animal medicines, and acquire new biologic and vaccine capabilities. We are excited about these new opportunities to improve animal health and protein production, and deliver greater value to our customers”
